Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Noopur Raje, M.D.

Co-Author

This page shows the publications co-authored by Noopur Raje and Andrew Yee.
Connection Strength

8.005
  1. How We Approach Smoldering Multiple Myeloma. J Clin Oncol. 2020 04 10; 38(11):1119-1125.
    View in: PubMed
    Score: 0.882
  2. Panobinostat and Multiple Myeloma in 2018. Oncologist. 2018 05; 23(5):516-517.
    View in: PubMed
    Score: 0.770
  3. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Future Oncol. 2018 Feb; 14(3):195-203.
    View in: PubMed
    Score: 0.753
  4. Sequencing of nontransplant treatments in multiple myeloma patients with active disease. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):495-503.
    View in: PubMed
    Score: 0.708
  5. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016 Nov; 17(11):1569-1578.
    View in: PubMed
    Score: 0.698
  6. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.591
  7. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging. 2012; 7:331-8.
    View in: PubMed
    Score: 0.528
  8. Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? Cancers (Basel). 2020 May 13; 12(5).
    View in: PubMed
    Score: 0.225
  9. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018 12 01; 4(12):e183267.
    View in: PubMed
    Score: 0.203
  10. Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precis Oncol. 2018; 2.
    View in: PubMed
    Score: 0.200
  11. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.195
  12. Myeloma and Bone Disease. Curr Osteoporos Rep. 2017 10; 15(5):483-498.
    View in: PubMed
    Score: 0.187
  13. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 2017 08; 31(8):1760-1769.
    View in: PubMed
    Score: 0.177
  14. Role of decorin in multiple myeloma (MM) bone marrow microenvironment. J Bone Miner Res. 2015 Mar; 30(3):465-70.
    View in: PubMed
    Score: 0.157
  15. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015 May; 169(3):423-34.
    View in: PubMed
    Score: 0.157
  16. Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine. 2015 Jan; 2(1):71-3.
    View in: PubMed
    Score: 0.154
  17. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. . 2014 Nov; 13(11):2489-500.
    View in: PubMed
    Score: 0.151
  18. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
    View in: PubMed
    Score: 0.149
  19. Advances in supportive care for multiple myeloma. J Natl Compr Canc Netw. 2014 Apr; 12(4):502-11.
    View in: PubMed
    Score: 0.147
  20. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 2014 Sep; 28(9):1892-901.
    View in: PubMed
    Score: 0.146
  21. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia. 2013 Aug; 27(8):1715-21.
    View in: PubMed
    Score: 0.136
  22. Lifestyle considerations in multiple myeloma. Blood Cancer J. 2021 Oct 26; 11(10):172.
    View in: PubMed
    Score: 0.062
  23. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021 Nov; 23(11):1199-1211.
    View in: PubMed
    Score: 0.062
  24. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2021 Sep 16.
    View in: PubMed
    Score: 0.062
  25. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res. 2021 Sep 13.
    View in: PubMed
    Score: 0.062
  26. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:291-309.
    View in: PubMed
    Score: 0.059
  27. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer. 2019 Nov 01; 125(21):3692-3698.
    View in: PubMed
    Score: 0.054
  28. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
    View in: PubMed
    Score: 0.050
  29. Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. Skeletal Radiol. 2019 May; 48(5):773-779.
    View in: PubMed
    Score: 0.050
  30. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.050
  31. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.048
  32. Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma. Blood Cancer J. 2017 10 06; 7(10):e615.
    View in: PubMed
    Score: 0.047
  33. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016 11 02; 8(363):363ra147.
    View in: PubMed
    Score: 0.044
  34. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 05 12; 127(19):2355-6.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.